{"ticker": {"uuid": "7e209428-738e-480c-8496-f4d23b12c72d", "symbol": "GRCL", "name": "Gracell Biotechnologies Inc.", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNZXlTZHFHZVNxMktqZ0hVNURmdE1hUFpZZnlfdEVhMnVla2EyTWN6b2YwNkVhNllxUy1Bczl2a0ZUNk04Q3oyTEZSajdpMnFDVXJfRTlfLUdHQ05uS3FQZkhNWkJ0MDFENDJvRXR0ZGV1RDlYVmdWem96V29NeTg4YWRZWGNoMzM1emRoSExJbXdwZnJIWHpsYjVnT0FQVHZtUW5iVg?oc=5", "source_name": "Market source", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Gracell Biotechnologies Inc. v. Alpine Global Management LLC: Discovery Application (Cayman Islands)", "summary": "This article details a discovery application filed by Gracell Biotechnologies Inc. against Alpine Global Management LLC in the U.S. District Court for the Southern District of New York. The application seeks discovery for an \"appraisal proceeding\" in the Cayman Islands related to", "url": "https://www.offshorealert.com/gracell-biotechnologies-inc-v-alpine-global-management-llc-discovery-application-cayman-islands/", "source_name": "OffshoreAlert", "published_at": "2024-04-22T02:09:44", "published_display": "22 Apr 2024 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca Acquires Gracell Biotechnologies", "summary": "AstraZeneca has completed its acquisition of Gracell Biotechnologies Inc., a biopharmaceutical company specializing in cell therapies for cancer and autoimmune diseases. This acquisition integrates Gracell's clinical-stage CAR-T therapy, GC012F, into AstraZeneca's pipeline, targe", "url": "https://www.contractpharma.com/breaking-news/astrazeneca-acquires-gracell-biotechnologies/", "source_name": "Contract Pharma", "published_at": "2024-02-23T00:00:00", "published_display": "23 Feb 2024 00:00", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca completes Gracell Biotechnologies acquisition for $1.2bn", "summary": "AstraZeneca has finalized its $1.2bn acquisition of China-based biopharmaceutical company Gracell Biotechnologies, making Gracell a wholly owned subsidiary. This strategic move aims to bolster AstraZeneca's cell therapy pipeline with treatments for cancer and autoimmune diseases,", "url": "https://www.pharmaceutical-technology.com/news/astrazeneca-completes-gracell-acquisition/", "source_name": "Pharmaceutical Technology", "published_at": "2024-02-23T00:00:00", "published_display": "23 Feb 2024 00:00", "sentiment": "positive", "sentiment_pct": 70, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gracell Biotechnologies Acquisition Completed", "summary": "Gracell Biotechnologies announced today the completion of its acquisition by AstraZeneca. As a result, Gracell is no longer a publicly traded company and is now a wholly-owned subsidiary of AstraZeneca. Shareholders will receive $2.00 per share in cash and one contingent value ri", "url": "https://www.stocktitan.net/news/GRCL/gracell-biotechnologies-acquisition-sxjlblaufwci.html", "source_name": "Stock Titan", "published_at": "2024-02-22T04:39:41", "published_display": "22 Feb 2024 04:39", "sentiment": "negative", "sentiment_pct": 38, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acquisition of Gracell completed", "summary": "AstraZeneca announced the successful completion of its acquisition of Gracell Biotechnologies Inc. This acquisition enhances AstraZeneca's cell therapy pipeline with GC012F, a clinical-stage CAR-T therapy for multiple myeloma and autoimmune diseases. Gracell will now operate as a", "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/acquisition-of-gracell-completed.html", "source_name": "AstraZeneca", "published_at": "2024-02-22T02:59:32", "published_display": "22 Feb 2024 02:59", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma", "summary": "Gracell Biotechnologies announced that the FDA has cleared its Investigational New Drug (IND) application for a Phase 1 clinical trial of GC012F, its FasTCAR-T cell therapy, for the early-line treatment of multiple myeloma (ELMM). This marks the third U.S. IND clearance for GC012", "url": "https://www.stocktitan.net/news/GRCL/gracell-biotechnologies-announces-fda-clearance-of-ind-application-ydae87i2j2w8.html", "source_name": "Stock Titan", "published_at": "2024-01-29T21:51:34", "published_display": "29 Jan 2024 21:51", "sentiment": "positive", "sentiment_pct": 70, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca Bolsters Cellular Therapy Pipeline With Acquisition of Gracell Biotechnologies", "summary": "AstraZeneca is acquiring Gracell Biotechnologies Inc. for a deal potentially worth up to $1.2 billion, aiming to enhance its cellular therapy pipeline. The acquisition includes Gracell's FasTCAR platform, which is expected to improve the efficacy of CAR T-cell therapies and accel", "url": "https://www.pharmexec.com/view/astrazeneca-bolsters-cellular-therapy-pipeline-with-acquisition-of-gracell-biotechnologies", "source_name": "Pharmaceutical Executive", "published_at": "2024-01-02T00:00:00", "published_display": "02 Jan 2024 00:00", "sentiment": "positive", "sentiment_pct": 74, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca buys Chinese CAR-T biotech Gracell in a $1.2bn deal", "summary": "AstraZeneca has signed a definitive agreement to acquire Gracell Biotechnologies, a China-based CAR T-cell therapy biotech, for approximately $1.2 billion in combined upfront and potential contingent value payments. This acquisition aims to expand AstraZeneca's portfolio in chime", "url": "https://www.pharmaceutical-technology.com/news/astrazeneca-buys-chinese-car-t-biotech-gracell-in-a-1-2bn-deal/", "source_name": "Pharmaceutical Technology", "published_at": "2023-12-27T14:46:00", "published_display": "27 Dec 2023 14:46", "sentiment": "positive", "sentiment_pct": 70, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca to acquire Gracell, furthering cell therapy ambition across oncology and autoimmune diseases", "summary": "AstraZeneca has announced its definitive agreement to acquire Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company specializing in innovative cell therapies. This acquisition will expand AstraZeneca's cell therapy pipeline with GC012F, a novel CAR-T therapy ta", "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-to-acquire-gracell-furthering-cell-therapy-ambition-across-oncology-and-autoimmune-diseases.html", "source_name": "AstraZeneca", "published_at": "2023-12-26T14:58:18", "published_display": "26 Dec 2023 14:58", "sentiment": "positive", "sentiment_pct": 73, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gracell Biotechnologies to be acquired by AstraZeneca, furthering cell therapy ambition across oncology and autoimmune diseases", "summary": "AstraZeneca announced its intent to acquire Gracell Biotechnologies, a clinical-stage biopharmaceutical company focused on cell therapies. The acquisition, valued at up to $1.2 billion, targets Gracell's innovative FasTCAR-enabled BCMA/CD19 dual-targeting autologous CAR-T cell th", "url": "https://www.globenewswire.com/news-release/2023/12/26/2801029/0/en/gracell-biotechnologies-to-be-acquired-by-astrazeneca-furthering-cell-therapy-ambition-across-oncology-and-autoimmune-diseases.html", "source_name": "GlobeNewswire", "published_at": "2023-12-26T08:10:46", "published_display": "26 Dec 2023 08:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gracell Biotechnologies to Participate in Inaugural Cell Therapy for Autoimmune Disease Summit", "summary": "Gracell Biotechnologies Inc. (NASDAQ: GRCL), a clinical-stage biopharmaceutical company, announced its participation in the inaugural Cell Therapy for Autoimmune Disease Summit. The company's Chief Business Officer, Dr. Samuel Zhang, will present on developing next-generation CAR", "url": "https://www.globenewswire.com/news-release/2023/11/16/2781769/0/en/Gracell-Biotechnologies-to-Participate-in-Inaugural-Cell-Therapy-for-Autoimmune-Disease-Summit.html", "source_name": "GlobeNewswire", "published_at": "2023-11-16T17:09:51", "published_display": "16 Nov 2023 17:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gracell\u2019s BCMA/CD19 CAR-T GC012F Achieves 100% Stringent CR Rate in Newly Diagnosed Multiple Myeloma", "summary": "Gracell Biotechnologies' investigational CAR-T therapy, GC012F, has demonstrated a 100% stringent complete response (sCR) rate in newly diagnosed multiple myeloma (NDMM) patients during a phase 1 clinical trial. All 19 patients achieved sCR with minimal residual disease negativit", "url": "https://www.cgtlive.com/view/gracell-bcma-cd19-car-t-gc012f-achieves-100-stringent-cr-rate-newly-diagnosed-multiple-myeloma", "source_name": "CGTLive\u00ae", "published_at": "2023-10-02T18:08:56", "published_display": "02 Oct 2023 18:08", "sentiment": "positive", "sentiment_pct": 92, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gracell Biotechnologies\u2019 CEO Dr. William Cao Named to Prestigious PharmaVoice 100, Honoring Most Inspiring Life Science Leaders", "summary": "Dr. William Cao, Founder, Chairman, and CEO of Gracell Biotechnologies, has been named to the PharmaVoice 100, an honor recognizing inspiring leaders in the life sciences industry. This recognition highlights his over 30 years of experience and Gracell's commitment to developing ", "url": "https://finance.yahoo.com/news/gracell-biotechnologies-ceo-dr-william-132100820.html", "source_name": "Market source", "published_at": "2023-09-19T03:10:29", "published_display": "19 Sep 2023 03:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RA Capital Management, L.P. Acquires Significant Stake in Gracell Biotechnologies Inc.", "summary": "RA Capital Management, L.P. has acquired a significant stake in Gracell Biotechnologies Inc., purchasing over 48 million shares at $3.75 each, now holding 9.99% of the company's equity. This strategic investment by the Boston-based firm in the clinical-stage biopharmaceutical com", "url": "https://finance.yahoo.com/news/ra-capital-management-l-p-010233865.html", "source_name": "Market source", "published_at": "2023-08-21T05:09:38", "published_display": "21 Aug 2023 05:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gracell Biotechnologies Announces Up to $150 Million Private Placement Financing Joined by a Syndicate of Premier Healthcare Investors", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAJBVV95cUxNSzdUR3RGMkZTUFJZb2JhQ2ZwMUpJN1FuSE9OckRqcWExUk5pVUNCS1dPQjBpWk5vLTIwNHFia2NueE1USEQwaUtKbWtlSkY2aTVjUF9ya25lTDQxbURnaGlnZDMwLTBJX1JBdzBURnJ2MVhXbHRDRU5aOGxiaDFJV2t6T2hCUnpwQlZmSnhGNGJ3NVpGVXRvUXlpTmpONDg4LWVFakhHUXNBMFBBbHI1VjRlRkRyQTZvYjVOQXZSSnc1dk56aDBOZlBEdDZYRlppVzRFQmsyWThic21jMmNiaFAxM2hpOXgtVHFoTWRaYnd5YTNXX1JNRWU1RjZaekNxVXFjZ2NJQWo2b0JNaVRISnM0alc3VHdE?oc=5", "source_name": "PR Newswire", "published_at": "2023-08-07T07:00:00+00:00", "published_display": "07 Aug 2023 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gracell Biotechnologies Inc. (GRCL) Stock Forecast & Price Prediction 2026\u20132030", "summary": "", "url": "https://news.google.com/rss/articles/CBMiX0FVX3lxTFAtbWNqZTltdnc5WmpsZHhiTW41c0Zyc0dIdVlJaXVXc1I3cmt2eTdSajJmdjF1eGMzdEUxNElBTUNtQ1VVb2dIS2NlUUF0Q0g4WXQ2YUltakZ6Z1ZUX0VN?oc=5", "source_name": "CoinCodex", "published_at": "2023-04-06T00:47:20+00:00", "published_display": "06 Apr 2023 00:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gracell Biotechnologies\u2019 quest to unlock the CAR-T bottleneck", "summary": "Gracell Biotechnologies is developing CAR-T cell therapies aiming to solve manufacturing bottlenecks, reduce costs, and enable first-line treatment for solid tumors. The company's FasTCAR platform significantly shortens manufacturing time, and recent positive Phase 1 data for GC0", "url": "https://www.pharmavoice.com/news/Gracell-Biotechnologies-CAR-T-autologous-allogenic/639886/", "source_name": "Pharma Voice", "published_at": "2023-01-09T06:57:34", "published_display": "09 Jan 2023 06:57", "sentiment": "positive", "sentiment_pct": 90, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gracell Biotech Stock Has Over 100% Upside On Next-Gen CAR-T Platforms, Analyst Claims", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxObEtjUi1VS3lrSHhXOW1HLS1scm51cnUwMEZlTUFfWXByd3NvNUFGdUxwWktURF9iWVM0MDhVZ2NsT3hacGJNemk3WkFyTms1bE9mamI4bFMtcnVEYVVvQWQ0REJOeUFIYXZnT2xCUmNjMXQteDVzM0V6a3ZkZExVNGhB?oc=5", "source_name": "Market source", "published_at": "2022-12-08T08:00:00+00:00", "published_display": "08 Dec 2022 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gracell Biotechnologies Wins 2022 Fierce Life Sciences Innovation Award", "summary": "Gracell Biotechnologies Inc. announced its FasTCAR Autologous CAR-T Platform won the Biotech Innovation category at the 2022 Fierce Life Sciences Innovation Awards. The FasTCAR platform enables next-day manufacturing for CAR-T cell therapies, aiming to improve accessibility, redu", "url": "https://www.biospace.com/gracell-biotechnologies-wins-2022-fierce-life-sciences-innovation-award", "source_name": "BioSpace", "published_at": "2022-11-16T07:09:50", "published_display": "16 Nov 2022 07:09", "sentiment": "positive", "sentiment_pct": 91, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gracell Biotechnologies Appoints Accomplished Clinical Leader Dr. Wendy Li as Chief Medical Officer", "summary": "Gracell Biotechnologies has appointed Dr. Wendy Li as its new Chief Medical Officer. Dr. Li brings over 20 years of experience in oncology clinical development, medical affairs, and U.S. regulatory processes from various pharmaceutical companies. In her new role, she will oversee", "url": "https://www.biospace.com/gracell-biotechnologies-appoints-accomplished-clinical-leader-dr-wendy-li-as-chief-medical-officer", "source_name": "BioSpace", "published_at": "2022-08-01T12:10:27", "published_display": "01 Aug 2022 12:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gracell Biotechnologies to Participate in Two Upcoming Virtual Investor Conferences", "summary": "Gracell Biotechnologies Inc. announced its participation in two upcoming virtual investor conferences: the Jefferies China Biotech Summit and the Citi China Investor Conference 2021. The company will engage in one-on-one and small group meetings, and a fireside chat at the Jeffer", "url": "https://www.globenewswire.com/news-release/2021/10/15/2315017/0/en/Gracell-Biotechnologies-to-Participate-in-Two-Upcoming-Virtual-Investor-Conferences.html", "source_name": "GlobeNewswire", "published_at": "2021-10-15T08:30:00", "published_display": "15 Oct 2021 08:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gracell Biotechnologies Signs Exclusive License Agreement with FutureGen Biopharm to Develop Engineered Immune Cell Therapies Targeting Claudin 18.2 in Solid Tumors", "summary": "Gracell Biotechnologies has signed an exclusive license agreement with FutureGen Biopharm to develop engineered immune cell therapies targeting Claudin 18.2 (CLDN18.2) for solid tumors. This collaboration aims to combine Gracell's expertise in immune cell therapy with FutureGen's", "url": "https://www.prnewswire.com/news-releases/gracell-biotechnologies-signs-exclusive-license-agreement-with-futuregen-biopharm-to-develop-engineered-immune-cell-therapies-targeting-claudin-18-2-in-solid-tumors-301355538.html", "source_name": "PR Newswire", "published_at": "2021-08-16T19:45:54", "published_display": "16 Aug 2021 19:45", "sentiment": "positive", "sentiment_pct": 91, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gracell Biotechnologies (GRCL) Stock Price, News & Analysis $GRCL", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE56ZmlJWGhzVGd1bHVfVnlDR0Flak92eW40U1VzWWRsaG9RV1o4SG5GMFlzWC0yV2dzaEU5OE1vUGhPd3dKSzdpbk4wbWZINkIxaFphbGRnZHNXdw?oc=5", "source_name": "MarketBeat", "published_at": "2021-01-08T23:30:08+00:00", "published_display": "08 Jan 2021 23:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gracell Biotechnologies Raises $100 Million in Series C Funding to Advance Next Generation CAR-T Cell Therapies", "summary": "Gracell Biotechnologies, a clinical-stage biopharmaceutical company, announced it has secured $100 million in Series C funding led by Wellington Management Company, OrbiMed, and Morningside Ventures. The funding will advance the company's next-generation CAR-T cell therapies whic", "url": "https://www.biospace.com/gracell-biotechnologies-raises-100-million-in-series-c-funding-to-advance-next-generation-car-t-cell-therapies", "source_name": "BioSpace", "published_at": "2020-10-28T08:09:37", "published_display": "28 Oct 2020 08:09", "sentiment": "positive", "sentiment_pct": 92, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Gracell Biotechnologies Inc. v. Alpine Global Management LLC: Discovery Application (Cayman Islands)", "summary": "This article details a discovery application filed by Gracell Biotechnologies Inc. against Alpine Global Management LLC in the U.S. District Court for the Southern District of New York. The application seeks discovery for an \"appraisal proceeding\" in the Cayman Islands related to", "url": "https://www.offshorealert.com/gracell-biotechnologies-inc-v-alpine-global-management-llc-discovery-application-cayman-islands/", "source_name": "OffshoreAlert", "published_at": "2024-04-22T02:09:44", "published_display": "22 Apr 2024 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca Acquires Gracell Biotechnologies", "summary": "AstraZeneca has completed its acquisition of Gracell Biotechnologies Inc., a biopharmaceutical company specializing in cell therapies for cancer and autoimmune diseases. This acquisition integrates Gracell's clinical-stage CAR-T therapy, GC012F, into AstraZeneca's pipeline, targe", "url": "https://www.contractpharma.com/breaking-news/astrazeneca-acquires-gracell-biotechnologies/", "source_name": "Contract Pharma", "published_at": "2024-02-23T00:00:00", "published_display": "23 Feb 2024 00:00", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca completes Gracell Biotechnologies acquisition for $1.2bn", "summary": "AstraZeneca has finalized its $1.2bn acquisition of China-based biopharmaceutical company Gracell Biotechnologies, making Gracell a wholly owned subsidiary. This strategic move aims to bolster AstraZeneca's cell therapy pipeline with treatments for cancer and autoimmune diseases,", "url": "https://www.pharmaceutical-technology.com/news/astrazeneca-completes-gracell-acquisition/", "source_name": "Pharmaceutical Technology", "published_at": "2024-02-23T00:00:00", "published_display": "23 Feb 2024 00:00", "sentiment": "positive", "sentiment_pct": 70, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gracell Biotechnologies Acquisition Completed", "summary": "Gracell Biotechnologies announced today the completion of its acquisition by AstraZeneca. As a result, Gracell is no longer a publicly traded company and is now a wholly-owned subsidiary of AstraZeneca. Shareholders will receive $2.00 per share in cash and one contingent value ri", "url": "https://www.stocktitan.net/news/GRCL/gracell-biotechnologies-acquisition-sxjlblaufwci.html", "source_name": "Stock Titan", "published_at": "2024-02-22T04:39:41", "published_display": "22 Feb 2024 04:39", "sentiment": "negative", "sentiment_pct": 38, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acquisition of Gracell completed", "summary": "AstraZeneca announced the successful completion of its acquisition of Gracell Biotechnologies Inc. This acquisition enhances AstraZeneca's cell therapy pipeline with GC012F, a clinical-stage CAR-T therapy for multiple myeloma and autoimmune diseases. Gracell will now operate as a", "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/acquisition-of-gracell-completed.html", "source_name": "AstraZeneca", "published_at": "2024-02-22T02:59:32", "published_display": "22 Feb 2024 02:59", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma", "summary": "Gracell Biotechnologies announced that the FDA has cleared its Investigational New Drug (IND) application for a Phase 1 clinical trial of GC012F, its FasTCAR-T cell therapy, for the early-line treatment of multiple myeloma (ELMM). This marks the third U.S. IND clearance for GC012", "url": "https://www.stocktitan.net/news/GRCL/gracell-biotechnologies-announces-fda-clearance-of-ind-application-ydae87i2j2w8.html", "source_name": "Stock Titan", "published_at": "2024-01-29T21:51:34", "published_display": "29 Jan 2024 21:51", "sentiment": "positive", "sentiment_pct": 70, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca Bolsters Cellular Therapy Pipeline With Acquisition of Gracell Biotechnologies", "summary": "AstraZeneca is acquiring Gracell Biotechnologies Inc. for a deal potentially worth up to $1.2 billion, aiming to enhance its cellular therapy pipeline. The acquisition includes Gracell's FasTCAR platform, which is expected to improve the efficacy of CAR T-cell therapies and accel", "url": "https://www.pharmexec.com/view/astrazeneca-bolsters-cellular-therapy-pipeline-with-acquisition-of-gracell-biotechnologies", "source_name": "Pharmaceutical Executive", "published_at": "2024-01-02T00:00:00", "published_display": "02 Jan 2024 00:00", "sentiment": "positive", "sentiment_pct": 74, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca buys Chinese CAR-T biotech Gracell in a $1.2bn deal", "summary": "AstraZeneca has signed a definitive agreement to acquire Gracell Biotechnologies, a China-based CAR T-cell therapy biotech, for approximately $1.2 billion in combined upfront and potential contingent value payments. This acquisition aims to expand AstraZeneca's portfolio in chime", "url": "https://www.pharmaceutical-technology.com/news/astrazeneca-buys-chinese-car-t-biotech-gracell-in-a-1-2bn-deal/", "source_name": "Pharmaceutical Technology", "published_at": "2023-12-27T14:46:00", "published_display": "27 Dec 2023 14:46", "sentiment": "positive", "sentiment_pct": 70, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca to acquire Gracell, furthering cell therapy ambition across oncology and autoimmune diseases", "summary": "AstraZeneca has announced its definitive agreement to acquire Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company specializing in innovative cell therapies. This acquisition will expand AstraZeneca's cell therapy pipeline with GC012F, a novel CAR-T therapy ta", "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-to-acquire-gracell-furthering-cell-therapy-ambition-across-oncology-and-autoimmune-diseases.html", "source_name": "AstraZeneca", "published_at": "2023-12-26T14:58:18", "published_display": "26 Dec 2023 14:58", "sentiment": "positive", "sentiment_pct": 73, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gracell Biotechnologies to be acquired by AstraZeneca, furthering cell therapy ambition across oncology and autoimmune diseases", "summary": "AstraZeneca announced its intent to acquire Gracell Biotechnologies, a clinical-stage biopharmaceutical company focused on cell therapies. The acquisition, valued at up to $1.2 billion, targets Gracell's innovative FasTCAR-enabled BCMA/CD19 dual-targeting autologous CAR-T cell th", "url": "https://www.globenewswire.com/news-release/2023/12/26/2801029/0/en/gracell-biotechnologies-to-be-acquired-by-astrazeneca-furthering-cell-therapy-ambition-across-oncology-and-autoimmune-diseases.html", "source_name": "GlobeNewswire", "published_at": "2023-12-26T08:10:46", "published_display": "26 Dec 2023 08:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gracell Biotechnologies to Participate in Inaugural Cell Therapy for Autoimmune Disease Summit", "summary": "Gracell Biotechnologies Inc. (NASDAQ: GRCL), a clinical-stage biopharmaceutical company, announced its participation in the inaugural Cell Therapy for Autoimmune Disease Summit. The company's Chief Business Officer, Dr. Samuel Zhang, will present on developing next-generation CAR", "url": "https://www.globenewswire.com/news-release/2023/11/16/2781769/0/en/Gracell-Biotechnologies-to-Participate-in-Inaugural-Cell-Therapy-for-Autoimmune-Disease-Summit.html", "source_name": "GlobeNewswire", "published_at": "2023-11-16T17:09:51", "published_display": "16 Nov 2023 17:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gracell\u2019s BCMA/CD19 CAR-T GC012F Achieves 100% Stringent CR Rate in Newly Diagnosed Multiple Myeloma", "summary": "Gracell Biotechnologies' investigational CAR-T therapy, GC012F, has demonstrated a 100% stringent complete response (sCR) rate in newly diagnosed multiple myeloma (NDMM) patients during a phase 1 clinical trial. All 19 patients achieved sCR with minimal residual disease negativit", "url": "https://www.cgtlive.com/view/gracell-bcma-cd19-car-t-gc012f-achieves-100-stringent-cr-rate-newly-diagnosed-multiple-myeloma", "source_name": "CGTLive\u00ae", "published_at": "2023-10-02T18:08:56", "published_display": "02 Oct 2023 18:08", "sentiment": "positive", "sentiment_pct": 92, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gracell Biotechnologies\u2019 CEO Dr. William Cao Named to Prestigious PharmaVoice 100, Honoring Most Inspiring Life Science Leaders", "summary": "Dr. William Cao, Founder, Chairman, and CEO of Gracell Biotechnologies, has been named to the PharmaVoice 100, an honor recognizing inspiring leaders in the life sciences industry. This recognition highlights his over 30 years of experience and Gracell's commitment to developing ", "url": "https://finance.yahoo.com/news/gracell-biotechnologies-ceo-dr-william-132100820.html", "source_name": "Market source", "published_at": "2023-09-19T03:10:29", "published_display": "19 Sep 2023 03:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RA Capital Management, L.P. Acquires Significant Stake in Gracell Biotechnologies Inc.", "summary": "RA Capital Management, L.P. has acquired a significant stake in Gracell Biotechnologies Inc., purchasing over 48 million shares at $3.75 each, now holding 9.99% of the company's equity. This strategic investment by the Boston-based firm in the clinical-stage biopharmaceutical com", "url": "https://finance.yahoo.com/news/ra-capital-management-l-p-010233865.html", "source_name": "Market source", "published_at": "2023-08-21T05:09:38", "published_display": "21 Aug 2023 05:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gracell Biotechnologies Announces Up to $150 Million Private Placement Financing Joined by a Syndicate of Premier Healthcare Investors", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAJBVV95cUxNSzdUR3RGMkZTUFJZb2JhQ2ZwMUpJN1FuSE9OckRqcWExUk5pVUNCS1dPQjBpWk5vLTIwNHFia2NueE1USEQwaUtKbWtlSkY2aTVjUF9ya25lTDQxbURnaGlnZDMwLTBJX1JBdzBURnJ2MVhXbHRDRU5aOGxiaDFJV2t6T2hCUnpwQlZmSnhGNGJ3NVpGVXRvUXlpTmpONDg4LWVFakhHUXNBMFBBbHI1VjRlRkRyQTZvYjVOQXZSSnc1dk56aDBOZlBEdDZYRlppVzRFQmsyWThic21jMmNiaFAxM2hpOXgtVHFoTWRaYnd5YTNXX1JNRWU1RjZaekNxVXFjZ2NJQWo2b0JNaVRISnM0alc3VHdE?oc=5", "source_name": "PR Newswire", "published_at": "2023-08-07T07:00:00+00:00", "published_display": "07 Aug 2023 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gracell Biotechnologies Inc. (GRCL) Stock Forecast & Price Prediction 2026\u20132030", "summary": "", "url": "https://news.google.com/rss/articles/CBMiX0FVX3lxTFAtbWNqZTltdnc5WmpsZHhiTW41c0Zyc0dIdVlJaXVXc1I3cmt2eTdSajJmdjF1eGMzdEUxNElBTUNtQ1VVb2dIS2NlUUF0Q0g4WXQ2YUltakZ6Z1ZUX0VN?oc=5", "source_name": "CoinCodex", "published_at": "2023-04-06T00:47:20+00:00", "published_display": "06 Apr 2023 00:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gracell Biotechnologies\u2019 quest to unlock the CAR-T bottleneck", "summary": "Gracell Biotechnologies is developing CAR-T cell therapies aiming to solve manufacturing bottlenecks, reduce costs, and enable first-line treatment for solid tumors. The company's FasTCAR platform significantly shortens manufacturing time, and recent positive Phase 1 data for GC0", "url": "https://www.pharmavoice.com/news/Gracell-Biotechnologies-CAR-T-autologous-allogenic/639886/", "source_name": "Pharma Voice", "published_at": "2023-01-09T06:57:34", "published_display": "09 Jan 2023 06:57", "sentiment": "positive", "sentiment_pct": 90, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gracell Biotech Stock Has Over 100% Upside On Next-Gen CAR-T Platforms, Analyst Claims", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxObEtjUi1VS3lrSHhXOW1HLS1scm51cnUwMEZlTUFfWXByd3NvNUFGdUxwWktURF9iWVM0MDhVZ2NsT3hacGJNemk3WkFyTms1bE9mamI4bFMtcnVEYVVvQWQ0REJOeUFIYXZnT2xCUmNjMXQteDVzM0V6a3ZkZExVNGhB?oc=5", "source_name": "Market source", "published_at": "2022-12-08T08:00:00+00:00", "published_display": "08 Dec 2022 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gracell Biotechnologies Wins 2022 Fierce Life Sciences Innovation Award", "summary": "Gracell Biotechnologies Inc. announced its FasTCAR Autologous CAR-T Platform won the Biotech Innovation category at the 2022 Fierce Life Sciences Innovation Awards. The FasTCAR platform enables next-day manufacturing for CAR-T cell therapies, aiming to improve accessibility, redu", "url": "https://www.biospace.com/gracell-biotechnologies-wins-2022-fierce-life-sciences-innovation-award", "source_name": "BioSpace", "published_at": "2022-11-16T07:09:50", "published_display": "16 Nov 2022 07:09", "sentiment": "positive", "sentiment_pct": 91, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gracell Biotechnologies Appoints Accomplished Clinical Leader Dr. Wendy Li as Chief Medical Officer", "summary": "Gracell Biotechnologies has appointed Dr. Wendy Li as its new Chief Medical Officer. Dr. Li brings over 20 years of experience in oncology clinical development, medical affairs, and U.S. regulatory processes from various pharmaceutical companies. In her new role, she will oversee", "url": "https://www.biospace.com/gracell-biotechnologies-appoints-accomplished-clinical-leader-dr-wendy-li-as-chief-medical-officer", "source_name": "BioSpace", "published_at": "2022-08-01T12:10:27", "published_display": "01 Aug 2022 12:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gracell Biotechnologies to Participate in Two Upcoming Virtual Investor Conferences", "summary": "Gracell Biotechnologies Inc. announced its participation in two upcoming virtual investor conferences: the Jefferies China Biotech Summit and the Citi China Investor Conference 2021. The company will engage in one-on-one and small group meetings, and a fireside chat at the Jeffer", "url": "https://www.globenewswire.com/news-release/2021/10/15/2315017/0/en/Gracell-Biotechnologies-to-Participate-in-Two-Upcoming-Virtual-Investor-Conferences.html", "source_name": "GlobeNewswire", "published_at": "2021-10-15T08:30:00", "published_display": "15 Oct 2021 08:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gracell Biotechnologies Signs Exclusive License Agreement with FutureGen Biopharm to Develop Engineered Immune Cell Therapies Targeting Claudin 18.2 in Solid Tumors", "summary": "Gracell Biotechnologies has signed an exclusive license agreement with FutureGen Biopharm to develop engineered immune cell therapies targeting Claudin 18.2 (CLDN18.2) for solid tumors. This collaboration aims to combine Gracell's expertise in immune cell therapy with FutureGen's", "url": "https://www.prnewswire.com/news-releases/gracell-biotechnologies-signs-exclusive-license-agreement-with-futuregen-biopharm-to-develop-engineered-immune-cell-therapies-targeting-claudin-18-2-in-solid-tumors-301355538.html", "source_name": "PR Newswire", "published_at": "2021-08-16T19:45:54", "published_display": "16 Aug 2021 19:45", "sentiment": "positive", "sentiment_pct": 91, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gracell Biotechnologies (GRCL) Stock Price, News & Analysis $GRCL", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE56ZmlJWGhzVGd1bHVfVnlDR0Flak92eW40U1VzWWRsaG9RV1o4SG5GMFlzWC0yV2dzaEU5OE1vUGhPd3dKSzdpbk4wbWZINkIxaFphbGRnZHNXdw?oc=5", "source_name": "MarketBeat", "published_at": "2021-01-08T23:30:08+00:00", "published_display": "08 Jan 2021 23:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gracell Biotechnologies Raises $100 Million in Series C Funding to Advance Next Generation CAR-T Cell Therapies", "summary": "Gracell Biotechnologies, a clinical-stage biopharmaceutical company, announced it has secured $100 million in Series C funding led by Wellington Management Company, OrbiMed, and Morningside Ventures. The funding will advance the company's next-generation CAR-T cell therapies whic", "url": "https://www.biospace.com/gracell-biotechnologies-raises-100-million-in-series-c-funding-to-advance-next-generation-car-t-cell-therapies", "source_name": "BioSpace", "published_at": "2020-10-28T08:09:37", "published_display": "28 Oct 2020 08:09", "sentiment": "positive", "sentiment_pct": 92, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNZXlTZHFHZVNxMktqZ0hVNURmdE1hUFpZZnlfdEVhMnVla2EyTWN6b2YwNkVhNllxUy1Bczl2a0ZUNk04Q3oyTEZSajdpMnFDVXJfRTlfLUdHQ05uS3FQZkhNWkJ0MDFENDJvRXR0ZGV1RDlYVmdWem96V29NeTg4YWRZWGNoMzM1emRoSExJbXdwZnJIWHpsYjVnT0FQVHZtUW5iVg?oc=5", "source_name": "Market source", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxNeEtmMFI0aDZ3MS1STFpyZzVtZzlHWEhacF9IdEE4ZVZOOXlnbHBLSWV3WjVzRnA1MjVWQjFzRERIY29QaGdlVlVaOXBvT1lmbWlIZnd2d19qVXdmeGcwZlplWDJ4REZ2S3hUX0VfaVBsNlBQOW9KOUJteTZLbFljRC1VZmdDN2pUWExlanUyRjhuVEwtQ3AwWV84dDdHUXB1bVFvLXU1ZDJxMU5PTG9QMk9KWDNtdEZhSEM2aTI3Z2RiY2FJYWJZM0l2bHhHazRQcnJMX1hvVGFKUWQ4bi1qTGxNVHZZd1nSAewBQVVfeXFMTm1HOFFxSGR3TUhXTDAtQjFvN2VPMkI4dU1JWXYxMDVNYm5kX1ZLSFpwWmdWbl9aaW5FdEhZNnNYbmFNM1pXTVRxVUI0cFlhcmp0ME1MRFRxV2FadGtXZ0tSX0ZfTjZ0dEdYMEptU3hJUmtycEJ3TTdGV3NjRDllcmZBLXNUX2p2MDVEY21wQXExdkNUVWxrc0c4Rkg5NVlhY0hhWmVmQ0VhWFJDS2NGbE9GT0IyYUZRckRJblRMTkxoN1RkaDBTaVN6T2tNbC1IQUlubHc4bjkzekNMWGNtZjRpd3hQSDFTYlRUZUk?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 77, "total_relevant": 31, "sentiment_summary": {"positive": 18, "negative": 2, "neutral": 11, "score": 68, "total": 31, "label": "Constructive news tone", "tone": "positive"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 72, "events": [{"event": "general", "label": "Market update", "weight": 5.5, "count": 10}, {"event": "deals", "label": "Deals and strategy", "weight": 4.95, "count": 9}, {"event": "earnings", "label": "Earnings", "weight": 2.89, "count": 7}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.65, "count": 3}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}], "positive_events": 18, "negative_events": 2}, "market_context": {"has_market_context": true, "latest_close": 10.25, "latest_week": "2026-06-19", "one_week_move": 0.0, "four_week_move": 0.0, "twelve_week_move": 0.0, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": -0.54725, "market_dynamics_buy_signal": false, "relative_strength": -7.79674, "fair_value_gap": 81.9, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "negative", "expectation_probability": 15.814, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+0.0% over one week, +0.0% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 67, "badges": ["Sentiment confirms active trend", "Positive but stretched"], "opportunities": ["Constructive tone aligns with the Sharemaestro trend signal."], "risks": ["Constructive tone is arriving with price materially above fair value."], "event_label": "Market update", "sentiment_word": "constructive"}, "charts": {"sources": [{"label": "Market source", "count": 8}, {"label": "GlobeNewswire", "count": 3}, {"label": "BioSpace", "count": 3}, {"label": "simplywall.st", "count": 2}, {"label": "Pharmaceutical Technology", "count": 2}, {"label": "Stock Titan", "count": 2}, {"label": "AstraZeneca", "count": 2}, {"label": "PR Newswire", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 24}, {"label": "Industry context", "count": 7}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 10}, {"label": "Deals and strategy", "count": 9}, {"label": "Earnings", "count": 7}, {"label": "Regulatory and legal", "count": 3}, {"label": "Guidance", "count": 1}, {"label": "Analyst action", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "68/100", "tone": "positive", "text": "Constructive news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "positive", "text": "72/100 classification confidence."}, {"label": "Company focus", "value": "24", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+0.0% over one week, +0.0% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Gracell Biotechnologies Inc. v. Alpine Global Management LLC: Discovery Application (Cayman Islands)"}], "updated_at": "2026-06-22T11:14:52.669331+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}